The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

Palantir Technologies stock has surged more than 2,000% since it launched its AI data mining solution. The stock looks extraordinarily expensive when measured using the most common valuation metrics.

Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...

Private equity firm Cinven is considering a sale of German software company think-cell, which could be valued at as much as €3 billion ($3.5 billion) in a deal, according to people familiar with the ...

Combining Rituxan with Mavenclad or Zelboraf upfront can extend remissions safely and should become standard first-line therapy for hairy cell leukemia. Combining Rituxan (rituximab) with Mavenclad ...

A Wake Forest woman tried and over and over again to get Verizon to cancel her husband's phone service to no avail. She finally contacted 5 On Your Side and, within a week, the matter was resolved. A ...

Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

Shane Larkin: So I think the combination of like the flair, the excitement, the talent, the IQ, all of it, and a 23-year-old kid that is only going to continue to grow and become better. I mean, no ...